SuperworthCareDx CDNA
- Market cap
- $3.6B
- PE
- 33.4×
- 2y median 19.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.8×
- EV/EBIT
- 29.3×
- Revenue, 12 months
- $458.1M
- +34% on a year ago
- Net margin
- 24.2%
- Free cash flow yield
- n/m
- not a meaningful number
CareDx trades at 33.4× trailing earnings, pricier than 99% of the last ten years. Revenue was $458.1M over the last twelve months, up 34% on a year earlier with a 24% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $67.2M−15% | $65.6M−20% | $72M−7% | $92.3M+31% | $82.9M+23% | $86.6M+32% | $84.7M+18% | $86.7M−6% | $100.1M+21% | $108.4M+25% | $117.7M+39% | $131.9M+52% | |
| Cost of revenue | $24.5M−13% | $25.6M−13% | $25.9M−0% | $28M+8% | $27.6M+12% | $28.2M+10% | $28.4M+10% | $28.7M+2% | $30.7M+11% | $35.5M+26% | $33.6M+18% | $35M+22% |
| Gross profit | $42.7M−16% | $40M−25% | $46.1M−10% | $64.3M+45% | $55.3M+30% | $58.4M+46% | $56.3M+22% | $58M−10% | $69.4M+26% | $72.9M+25% | $84.1M+49% | $97M+67% |
| R&D | $19M−15% | $18.3M−23% | $18.7M−23% | $19.7M−3% | $17.5M−8% | $16.6M−9% | $18.5M−1% | $16.8M−15% | $16.8M−4% | $19.3M+16% | $21.4M+16% | $22.4M+33% |
| SG&A | $52.4M+14% | $46.5M−4% | $50M−3% | $51.9M+2% | $51.5M−2% | $53.7M+15% | $45.8M−8% | $52M+0% | $52.9M+3% | $59.6M+11% | $60.9M+33% | $74.3M+43% |
| −$28.8M+66% | −$122.6M+541% | −$22.6M−7% | −$7.3M−74% | −$13.7M−52% | $84.4M | −$13.4M−41% | −$11.1M+52% | −$246K−98% | −$6M | $1.2M | $113.2M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$23.6M+41% | −$117.9M+550% | −$20M−16% | −$4.6M−82% | −$10.4M−56% | $87.9M | −$10.3M−49% | −$8.7M+89% | $1.7M | −$3.8M | $2.8M | $114.5M |
| −$80K | $165K−5% | −$83K | $22K | $200K | $171K+4% | $58K | −$117K | −$15K | $345K+102% | −$32K | $3.9M | |
| Net income | −$23.5M+39% | −$118.1M+544% | −$19.9M−16% | −$4.6M−82% | −$10.6M−55% | $87.7M | −$10.4M−48% | −$8.6M+85% | $1.7M | −$4.1M | $2.8M | $110.6M |
| −$0.43+34% | −$2.21+550% | −$0.38−14% | −$0.09−80% | −$0.20−54% | $1.51 | −$0.19−50% | −$0.16+78% | $0.03 | −$0.08 | $0.05 | $2.07 | |
| 54.2M+1% | 53.4M−0% | 51.7M−4% | 52.2M−3% | 52.9M−2% | 58.1M+9% | 55.3M+7% | 54.3M+4% | 53.7M+2% | 51.1M−12% | 53.1M−4% | 53.4M−2% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them. 47 periods, Q2 FY13 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest CareDx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CDNACareDx | $3.6B | 33.4× | 19.1× | n/m | 7.8× | +34% | 24.2% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | n/m | 3.5× | −0% | 4.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| Peer median | $9.5B | 42.0× | 34.7× | 17.4× | 5.1× | +8% | 9.3% |
Investors who own it
Investors we follow who held CareDx at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.4% of portfoliotrimmed
- Ron BaronBaron Capital0.1% of portfoliotrimmed
More on CareDx
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 39Diagnostics and research stocks with the highest profit margins
- #1of 17Diagnostics and research stocks with the fastest earnings growth
- #7of 42Diagnostics and research stocks with the fastest revenue growth
- #4of 20Diagnostics and research stocks with the lowest PE ratio
- #10of 25Diagnostics and research stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .